

Highly Specialised Technology Committee Interests Register

Topic: Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

Publication Date: TBC

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|------------------------------|-----------------|----------------------|---|-------------------|--|
| Doctor Elizabeth Toy | Clinical Expert | Indirect - financial | <p>Attendance at ESMO 2023 (including conference fees, travel and accommodation) where a number of trials and investigational products relating to lung cancer were presented was sponsored by MSD - Value unknown.</p> <p>Elizabeth has given invited talks to Astra Zeneca on the subject of lung cancer pathways and has received honoraria for attendance at advisory boards in relation to integration of their products in lung cancer management pathways</p> <p>Elizabeth has taken part in advisory boards regarding Selpercatinib ,another small molecule therapy, for Lilly Oncology, however this in not relevant to this appraisal</p> | 24/11/2024 | <i>It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal</i> |
| Professor Alistair Greystoke | Clinical Expert | Direct – financial | Alistair declared the following interest: Previous advisory board and speaker fees from AstraZeneca: none related to this appraisal. | 19/06/2025 | It was agreed that Alistairs's declaration would not prevent them from participating |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|------|-------------------|---------------------|-------------------------|----------------------|-------------------------------------|
| | | | | | in discussions on this appraisal |

DRAFT